Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836

Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003)

Related Keywords

Australia ,Kostenloser Wertpapierhandel ,Desmond James ,Paul Willems ,Trophic Communications ,Vaccinology At Ghent University ,Osivaxt Cell ,Alexandre Le Vert ,Chief Medical Officer ,Dose Optimization Study ,Ghent University ,Combination Trial ,Quadrivalent Influenza Vaccine ,T Andb Cell ,Media Inquiries ,Osivax ,Rovides ,Linical ,Development ,Update ,Head ,Influenza ,Vaccine ,Candidate ,Vx836 ,